key: cord-0746309-iw6pdweh authors: Oliver, Madeleine E.; Hinks, Timothy S. C. title: Azithromycin in viral infections date: 2020-09-23 journal: Rev Med Virol DOI: 10.1002/rmv.2163 sha: c7d699802fda42ecb89ea91a26d01e73a0b0f2a4 doc_id: 746309 cord_uid: iw6pdweh Azithromycin (AZM) is a synthetic macrolide antibiotic effective against a broad range of bacterial and mycobacterial infections. Due to an additional range of anti‐viral and anti‐inflammatory properties, it has been given to patients with the coronaviruses SARS‐CoV or MERS‐CoV. It is now being investigated as a potential candidate treatment for SARS‐CoV‐2 having been identified as a candidate therapeutic for this virus by both in vitro and in silico drug screens. To date there are no randomised trial data on its use in any novel coronavirus infection, although a large number of trials are currently in progress. In this review, we summarise data from in vitro, murine and human clinical studies on the anti‐viral and anti‐inflammatory properties of macrolides, particularly AZM. AZM reduces in vitro replication of several classes of viruses including rhinovirus, influenza A, Zika virus, Ebola, enteroviruses and coronaviruses, via several mechanisms. AZM enhances expression of anti‐viral pattern recognition receptors and induction of anti‐viral type I and III interferon responses. Of relevance to severe coronavirus‐19 disease (COVID‐19), which is characterised by an over‐exuberant innate inflammatory response, AZM also has anti‐inflammatory properties including suppression of IL‐1beta, IL‐2, TNF and GM‐CSF. AZM inhibits T cells by inhibiting calcineurin signalling, mammalian target of rapamycin activity and NFκB activation. AZM particularly targets granulocytes where it concentrates markedly in lysosomes, particularly affecting accumulation, adhesion, degranulation and apoptosis of neutrophils. Given its proven safety, affordability and global availability, tempered by significant concerns about antimicrobial stewardship, there is an urgent mandate to perform well‐designed and conducted randomised clinical trials. Azithromycin (AZM) is a second-generation, broad-spectrum, synthetic macrolide antibiotic used since the early 1980s 1,2 to treat a wide range of bacterial and mycobacterial infections of respiratory and skin infections. It is therefore on the WHO list of essential medications, 3 and manufactured on a large scale globally. Its antibacterial activity derives from its ability to bind to the 50S ribosomal subunit, inhibiting protein synthesis. 4 It also has an intriguing range of anti-viral and anti-inflammatory properties, and is now being investigated as a potential candidate treatment for viruses including SARS-CoV-2, which causes coronavirus-19 disease (COVID- 19) . It has been used as a treatment in previous coronavirus diseases during the epidemics of severe acute respiratory syndrome (SARS) in 2003 and Middle East respiratory syndrome (MERS) 5 in 2012, but to date there are no randomised trial data on its use in any novel coronavirus infection. Its proven safety, affordability and global availability make it an attractive candidate for repurposing as a treatment for COVID-19. Given the expected massive global impact of COVID-19, particularly in low-to-middle income countries, it is important not only to develop therapies that treat the virus successfully, but also to ensure that these therapies are readily implementable at all levels of development and economy. 6 This review summarizes the current understanding of the anti-viral and anti-inflammatory effects of AZM, with a view to A range of human in vitro and in vivo studies provide evidence of anti-viral activity of macrolides across a broad range of viral species and families (Table 1) . Some studies suggest improved symptom resolution and reduction, [17] [18] [19] [20] [21] [22] although not all studies have observed these effects. 23 ninefold reduction in viral shedding, respectively. 8 The use of AZM alone increased viral-induced interferons (IFNs) and interferonstimulated gene (ISG) mRNA expression and hence production of these gene products. 7, 8 In the latter study, while viral replication was suppressed, AZM did not suppress pro-inflammatory responses. In vivo data from the AMAZES study, the largest clinical trial of a long-term macrolide in airways disease, showed a striking 40% reduction in asthma exacerbations with AZM. 29 The mechanism is unknown, and would be consistent with an anti-viral effect, although metagenomic analyses suggest an antibacterial effect reducing This is of relevance to coronaviruses as type I IFN inhibit replication of both SARS-CoV 37 and SARS-CoV-2 38 in vitro. RV replication was also inhibited by the macrolides erythromycin 39 In a randomised trial in patients with influenza A receiving oseltamivir, 5 days' adjunctive AZM 500 mg daily was associated with more rapid reductions in plasma concentrations of IL-6, IL-8, IL-17, CXCL9, soluble tissue necrosis factor (TNF) and C-reactive protein (CRP). 16 infection. 43 However, the effect was not sustained, and not associated with a change in virus-induced weight loss, a sensitive measurement of influenza pathology. Another study found AZM reduced lung viral titres at day 6 post infection, though the effects were not additive to that achieved with oseltamivir in terms of survival, viral titres or cytokine levels, 46 and so these data remain conflicting. 47 In a separate influenza study, AZM decreased total leukocyte accumulation in lung tissue and BAL, with the largest reduction being in neutrophils, and associated with decreased inflammatory mediators. In a drug screen of 2177 compounds against the flavivirus Zika, AZM reduced viral proliferation and virus-induced cytopathic effects in glial cell lines and human astrocytes. 11 AZM was similarly evaluated in a drug screen for its efficacy as a therapy for Ebola. 14 While AZM demonstrated high in vitro potency (50% effective concentration [EC 50 ] = 5.1 μM) and low toxicity, when tested in an in vivo mouse model it did not consistently improve survival in mice or guinea pigs. Enterovirus A71 (EV-A71) causes hand, foot and mouth disease in young children. AZM and spiramycin (another macrolide) provided significant in vivo protection against EV-A71 infection in mice. 13 Spiramycin impaired EV-A71 viral RNA synthesis, and it is likely spiramycin and AZM work through a common mechanism, after viral entry, impairing viral RNA synthesis either directly or indirectly. 55 This combination has been tested in non-human primates, where a significant anti-viral effect was not seen in the five macaques which received AZM in addition to hydroxychloroquine. 56 AZM is rapidly absorbed after oral administration with a large volume of distribution 109 (Table 2 ). 70 One pathway for macrolide immunomodulation is through binding to macrophilin-12 inhibiting calcineurin and thus T cell activation, via the same mechanism as tacrolimus, 29 with consequent downstream inhibition of many immune cells including eosinophils and basophils. 68 Macrolides also inhibit mammalian target of rapamycin (mTOR) activity, also important in T cell activation and granulocyte differentiation, 115 suppressing cell proliferation and CD4 + T cell cytokine secretion. 116 In vitro AZM modulated differentiation and maturation of dendritic cells towards a regulatory phenotype with increased phagocytic capacity, 88 Abbreviations: CCL, C-C motif ligand; CD, cluster of differentiation; CF, cystic fibrosis; CXCL, C-X-C motif ligand; DPB, diffuse panbronchiolitis; COX, cyclooxygenase; cPLA2, cytosolic phospholipase A2; ERK, extracellular signal-regulated kinase; GM-CSF, granulocyte-macrophage colony-stimulating factor (CSF2); IL, interleukin; MAPK, mitogen-activated protein kinase; MCL1, myeloid cell leukaemia sequence 1; NALP3, NACHT, LRR, and PYD domainscontaining protein 3; PGE2, Prostaglandin E2; TGF-beta, transforming growth factor beta. Beyond its anti-viral properties, the anti-inflammatory effects of AZM It is understandable therefore, that more than 80 clinical trials have been designed to test AZM efficacy in COVID-19 (Table S1 ). These differ significantly from each other according to dosing regime, duration of therapy, whether being used in combination with hydroxychloroquine and, critically, according to the population being Given the significant clinical utility of AZM as an antibiotic, the current rapid spread of antimicrobial resistance is of particular concern. Widespread use of AZM to treat viral infections runs an inevi- Data sharing not applicable to this article as no datasets were generated or analysed during the current study. Timothy S. C. Hinks https://orcid.org/0000-0003-0699-2373 Azahomoerythromycin D derivative and intermediates therefor 11-Aza-10-deoxo-10-dihydroerythromycin A and derivatives thereof as well as a process for their preparation World Health Organization. Model List of Essential Medicines Effects of Macrolide Antibiotics on Ribosome Function Macrolides in critically ill patients with Middle East respiratory syndrome Global coalition to accelerate COVID-19 clinical research in resource-limited settings Azithromycin induces anti-viral responses in bronchial epithelial cells Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells Identification of novel macrolides with antibacterial, anti-inflammatory and type I and III IFNaugmenting activity in airway epithelium Reduction of coronavirus burden with mass azithromycin distribution Zika virus cell tropism in the developing human brain and inhibition by azithromycin Azithromycin protects against Zika virus infection by upregulating virus-induced type I and III interferon responses Spiramycin and azithromycin, safe for administration to children, exert antiviral activity against enterovirus A71 in vitro and in vivo Evaluation of Ebola virus inhibitors for drug repurposing Adjunctive therapy with azithromycin for moderate and severe acute respiratory distress syndrome: a retrospective, propensity score-matching analysis of prospectively collected data at a single center Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: a randomized controlled trial Immunomodulator clarithromycin enhances mucosal and systemic immune responses and reduces re-infection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitors: a retrospective analysis Efficacy of clarithromycinnaproxen-oseltamivir combination in the treatment of patients hospitalized for influenza a(H3N2) infection: an open-label randomized, controlled, phase IIb/III trial Additional treatment with clarithromycin reduces fever duration in patients with influenza Macrolide antibiotics and survival in patients with acute lung injury Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial Effect of maclorides on duration and resolution of symptoms and complication of pneumonia in children with influenza A single dose of azithromycin does not improve clinical outcomes of children hospitalised with bronchiolitis: a randomised, placebo-controlled trial Macrolidebased regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia Azithromycin therapy in hospitalized infants with acute bronchiolitis is not associated with better clinical outcomes: a randomized, double-blinded, and placebocontrolled clinical trial Dutch antibiotics in RSVTRG. Azithromycin does not improve disease course in hospitalized infants with respiratory syncytial virus (RSV) lower respiratory tract disease: a randomized equivalence trial Macrolides for chronic asthma Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial The effect of telithromycin in acute exacerbations of asthma Community study of role of viral infections in exacerbations of asthma in 9-11 year old children Host immune responses to rhinovirus: mechanisms in asthma Long-term azithromycin reduces Haemophilus influenzae and increases antibiotic resistance in severe asthma Airway abundance of Haemophilus influenzae predicts response to azithromycin in adults with persistent uncontrolled asthma influenzae potentiates airway epithelial cell responses to rhinovirus by increasing ICAM-1 and TLR3 expression Effect of clarithromycin on rhinovirus-16 infection in A549 cells Severe acute respiratory syndromerelated coronavirus is inhibited by interferon-alpha SARS-CoV-2 is sensitive to type I interferon pretreatment Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells Bafilomycin A(1) inhibits rhinovirus infection in human airway epithelium: effects on endosome and ICAM-1 Clarithromycin inhibits progeny virus production from human influenza virusinfected host cells Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice Leucomycin A3, a 16-membered macrolide antibiotic, inhibits influenza A virus infection and disease progression The combination of oseltamivir with azithromycin does not show additional benefits over oseltamivir monotherapy in mice infected with influenza A(H1N1)pdm2009 virus Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis SARS and MERS: recent insights into emerging coronaviruses Remdesivir for the treatment of Covid-19-preliminary report Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Focusing on the unfolded protein response and autophagy related pathways to reposition common approved drugs against COVID-19 Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clincial trial Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19) Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates Covid-19: time for a paradigm change Azithromycin for prevention of exacerbations of COPD A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation Immunomodulatory effects of macrolide antibiotics-part 1: biological mechanisms The effects of azithromycin on patients with diffuse panbronchiolitis: a retrospective study of 29 cases Improvement of survival in patients with diffuse panbronchiolitis treated with lowdose erythromycin Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis Azithromycin treats diffuse panbronchiolitis by targeting T cells via inhibition of mTOR pathway N 0 -substituted-2 0 -O,3 0 -Ncarbonimidoyl bridged macrolides: novel anti-inflammatory macrolides without antimicrobial activity Chlamydia pneumoniae activates nuclear factor kappaB and activator protein 1 in human vascular smooth muscle and induces cellular proliferation Azithromycin treatment modulates the extracellular signal-regulated kinase mediated pathway and inhibits inflammatory cytokines and chemokines in epithelial cells from infertile women with recurrent Chlamydia trachomatis infection Cyclosporin A and FK506 reduce interleukin-5 mRNA abundance by inhibiting gene transcription Macrolide antibiotics inhibit prostaglandin E2 synthesis and mRNA expression of prostaglandin synthetic enzymes in human leukocytes Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells Naringin attenuates EGF-induced MUC5AC secretion in A549 cells by suppressing the cooperative activities of MAPKs-AP-1 and IKKs-IkappaB-NF-kappaB signaling pathways Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells The macrolide antibiotic azithromycin interacts with lipids and affects membrane organization and fluidity: studies on Langmuir-Blodgett monolayers, liposomes and J774 macrophages Azithromycin, a lysosomotropic antibiotic, has distinct effects on fluid-phase and receptor-mediated endocytosis, but does not impair phagocytosis in J774 macrophages Hyperactivity of cathepsin B and other lysosomal enzymes in fibroblasts exposed to azithromycin, a dicationic macrolide antibiotic with exceptional tissue accumulation Druginduced phospholipidosis is caused by blockade of mannose 6-phosphate receptor-mediated targeting of lysosomal enzymes Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis Distribution of orally administered azithromycin in various blood compartments Different effects of telithromycin on MUC5AC production induced by human neutrophil peptide-1 or lipopolysaccharide in NCI-H292 cells compared with azithromycin and clarithromycin Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects Immunomodulatory effects of macrolides in the lung: lessons from in-vitro and in-vivo models Mechanisms of the macrolide-induced inhibition of superoxide generation by neutrophils Clarithromycin targets neutrophilic airway inflammation in refractory asthma Fourteen-member macrolides promote the phosphatidylserine receptor-dependent phagocytosis of apoptotic neutrophils by alveolar macrophages Azithromycin drives in vitro GM-CSF/IL-4-induced differentiation of human blood monocytes toward dendritic-like cells with regulatory properties Azithromycin alters macrophage phenotype Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice Azithromycin and clarithromycin inhibit lipopolysaccharide-induced murine pulmonary neutrophilia mainly through effects on macrophage-derived granulocytemacrophage colony-stimulating factor and interleukin-1beta Azithromycin decreases NALP3 mRNA stability in monocytes to limit inflammasome-dependent inflammation Leaky lysosomes in lung transplant macrophages: azithromycin prevents oxidative damage The effect of azithromycin and clarithromycin on ex vivo interleukin-8 (IL-8) release from whole blood and IL-8 production by human alveolar macrophages Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells Efficacy of azithromycin in preventing lethal graft-versus-host disease The effect of azithromycin on the maturation and function of murine bone marrow-derived dendritic cells Effect of azithromycin on natural killer cell function Macrolides inhibit epithelial cell-mediated neutrophil survival by modulating granulocyte macrophage colony-stimulating factor release Azithromycin has an antiproliferative and autophagic effect on airway smooth muscle cells Azithromycin has a direct relaxant effect on precontracted airway smooth muscle Novel effects of azithromycin on tight junction proteins in human airway epithelia Clinical features of patients infected with 2019 novel coronavirus in Wuhan Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-Oxododecanoyl) homoserine lactone in NCI-H292 cells Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drug interactions Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases Azithromycin: mechanisms of action and their relevance for clinical applications Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19 Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells Rapamycin inhibition of eosinophil differentiation attenuates allergic airway inflammation in mice Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity Azithromycin, clarithromycin and telithromycin inhibit MUC5AC induction by Chlamydophila pneumoniae in airway epithelial cells Antiinflammatory effects of azithromycin in cystic fibrosis airway epithelial cells Azithromycin suppresses interleukin-12p40 expression in lipopolysaccharide and interferon-gamma stimulated macrophages Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages Azithromycin inhibits nontypeable Haemophilus influenzae-induced MUC5AC expression and secretion via inhibition of activator protein-1 in human airway epithelial cells In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells Neutrophil elastase induces MUC5AC mucin production in human airway epithelial cells via a cascade involving protein kinase C, reactive oxygen species, and TNF-alpha-converting enzyme Human neutrophil elastase induces hypersecretion of mucin from well-differentiated human bronchial epithelial cells in vitro via a protein kinase C{delta}-mediated mechanism Azithromycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial Pathological findings of COVID-19 associated with acute respiratory distress syndrome Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan. China Intens Care Med The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus Dexamethasone in hospitalized patients with Covid-19-preliminary report Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19 A multi-centre open-label twoarm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial Adverse events in people taking macrolide antibiotics versus placebo for any indication Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome Additional supporting information may be found online in the Supporting Information section at the end of this article.